Search

The hydroxylation of dehydroepiandrosterone (DHEA) to 7α -hydroxy-5-androstene-17-one (7α-OH-DHEA) and 7β-hydroxy-5-androstene-17-one (7β-OH-DHEA) by Gibberella sp. CICC 2498 and Absidia coerulea CICC 41050 was investigated. The media ingredients were optimized. Single factors such as the DHEA concentration, culture time, medium volume, and inoculum rate were individually investigated to generate optimum biotransformation conditions. An orthogonal optimization process using a four-factor, three- level L9 (33) experiment was designed and performed. Finally, the maximum production of 7β-OH-DHEA from DHEA biotransformation by Absidia coerulea is 69.61%. This strategy would provide a possible way to enhance the 7β-OH-DHEA yield in the pharmaceutical industry.

Streptomyces noursei D-3-14 was taken as a starting strain and treated with UV (15 W, 30 cm) mutagenesis for 40 s for three consecutive rounds. High yielding strains were screened using chemical and biological potency determination, and the components of the fermentation products were detected using HPLC. Finally, the mutant strain Streptomyces noursei 72-22-1 with a chemical potency of 8912 (U/mL) and a biological potency of 5557 (U/mL) was obtained after the genetic stability evaluation. After optimization of the fermentation conditions, the chemical potency and biological potency of Streptomyces noursei 72-22-1 reached 14,082 U/mL and 10579 U/mL, respectively, which is 1.58 and 1.91 times those before optimization. HPLC analysis indicated that the mutant strain 72-22-1 displayed a higher content of polyfungin B. When equimolar nystatin A1, A3, and polyfungin B were tested for their fungicidal activities towards Saccharomyces cerevisiae ATCC 2061, polyfungin B exhibited a better efficacy than nystatin A1 and A3.